- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02959814
Diagnostic Accuracy of On-line Quantitative Flow Ratio (QFR). FAVOR II Europe-Japan (FAVOR II EJ)
Diagnostic Accuracy of On-line Quantitative Flow Ratio. Functional Assessment by Virtual Online Reconstruction (The FAVOR II Europe-Japan Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
Patients at high risk of having one or more coronary stenosis are evaluated routinely by invasive coronary angiography (CAG). Lesions are often quantified by QCA, but fractional flow reserve is increasingly used to assess functional significance of identified stenosis. FFR is assessed during CAG by advancing a wire with a pressure transducer towards the stenosis and measure the ratio in pressure between the two sides of the stenosis during medical induced maximum blood flow (hyperaemia).
The solid evidence for FFR evaluation of coronary stenosis and the relative simplicity in performing the measurements have supported adoption of an FFR based strategy in many centers but the need for interrogating the stenosis by a pressure wire, the cost of the wire, and the drug inducing hyperaemia limits more widespread adoption.
Quantitative Flow Ratio is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two angiographic projections.
The FAVOR I study (Tu et al.), showed promising results for core laboratory QFR analysis in selected patients.
The purpose of the FAVOR II study is to evaluate the feasibility and diagnostic precision of in-procedure QFR during CAG in comparison to QCA with FFR as gold standard for physiological lesion evaluation.
Hypothesis: QFR has superior sensitivity and specificity for detection of functional significant lesions in comparison to QCA with FFR as gold standard
Methods: Prospective, observational, multicenter study with inclusion of 310 patients.
Patients with indication for FFR are enrolled. At least two angiographic projections are acquired during resting conditions. QFR is calculated in-procedure using the Medis Suite application and simultaneously to the operator performing the FFR measurement. The QFR observer is blinded to the FFR measurement.
QFR is reassessed off-line by the Interventional Coronary Imaging Core Laboratory, Aarhus University, Denmark, blinded to FFR and in-procedure QFR results.
FFR is assessed by core laboratory reading, blinded to QFR results. All data are entered and stored in a protected and logged trial management system (TrialPartner, Aarhus University, Denmark).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Aarhus N, Denmark, 8200
- Aarhus University Hspital
-
-
-
-
-
Massy, France
- Institut Cardiovasculaire Paris Sud Massy
-
-
-
-
-
Essen, Germany
- Elizabeth Krankenhaus Essen
-
Giessen, Germany, 35392
- Universitätsklinikum Gießen
-
-
-
-
-
Caserta, Italy
- Azienda ospedaliera Sant'Anna e S. sebastiano di Caserta
-
Ferrara, Italy, 44124
- Azienda Ospedaliero-Universitaria di Ferrara, University of Ferrara
-
Mestre, Italy, 30174
- Ospedale Dell'Angelo Di Mestre
-
-
-
-
-
Gifu, Japan
- Gifu Heart Center
-
-
-
-
-
The Hague, Netherlands, 2545
- HagaZiekenhuis
-
-
-
-
-
Glasgow, United Kingdom, G81 4DY
- Golden Jubilee National Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Stable angina pectoris or secondary evaluation of stenosis after acute MI
- Age > 18 years
- Able to provide signed informed consent
- Angiographic inclusion criteria:
- Indication for FFR in at least one stenosis:
- Diameter stenosis of 30%-90% by visual estimate
- Reference vessel size > 2 mm in stenotic segment by visual estimate
Exclusion Criteria:
- Myocardial infarction within 72 hours
- Severe asthma or severe chronic obstructive pulmonary disease
- Severe heart failure (NYHA≥III)
- S-creatinine>150µmol/L or GFR<45 ml/kg/1.73m2
- Allergy to contrast media or adenosine
- Atrial fibrillation
- Angiographic exclusion criteria:
Lesion specific
- Below 30% and above 90% diameter stenosis by visual estimate.
- Reference size of vessel below 2 mm by visual estimation.
- Ostial LMCA lesions
- Ostial RCA lesions
- Distal LMCA lesions in combination with proximal Cx lesions
- Other bifurcation stenosis with lesions on both sides of a major shift (>1mm) in reference diameter Angiographic quality
- Poor image quality precluding contour detection
- Good contrast filling not possible
- Severe overlap of stenosed segments
- Severe tortuosity of target vessel
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity: Proportion of Patients With Positive QFR of FFR Positive Patients (True Positives) Compared to Proportion of Patients With Positive Percentual Diameter Stenosis (DS%) Assessed by 2D QCA of FFR Positive Patients (True Positives)
Time Frame: 1 hour
|
Positive FFR is defined as FFR≤0.80.
Positive QFR is defined as QFR≤0.80.
Positive DS% is defined as DS% > 50%
|
1 hour
|
Specificity: Proportion of Patients With Negative QFR of FFR Negative Patients (True Negatives) Compared to Proportion of Patients With Negative DS% Assessed by 2D QCA of FFR Negative Patients (True Negatives)
Time Frame: 1 hour
|
Negative FFR is defined as FFR>0.80.
Negative QFR is defined as QFR>0.80.
Negative DS% is defined as DS% ≤ 50%.
|
1 hour
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Patients With Successful QFR in Patients With Successful FFR (Feasibility)
Time Frame: 1 hour
|
1 hour
|
|
Proportion of Patients With Positive QFR of FFR Positive Patients (True Positives) (Sensitivity)
Time Frame: 1 hour
|
Positive FFR is defined as FFR≤0.80.
Positive QFR is defined as QFR≤0.80
|
1 hour
|
Proportion of Patients With Negative QFR of FFR Negative Patients (True Negatives) (Specificity)
Time Frame: 1 hour
|
Negative FFR is defined as FFR>0.80.
Negative QFR is defined as QFR>0.80
|
1 hour
|
Proportion of Patients With Positive FFR (True Positives) of Patients With Positive QFR (Positive Predictive Value)
Time Frame: 1 hour
|
Positive FFR is defined as FFR≤0.80.
Positive QFR is defined as QFR≤0.80
|
1 hour
|
Proportion of Patients With Negative FFR (True Negatives) of Patients With Negative QFR (Negative Predictive Value)
Time Frame: 1 hour
|
Negative FFR is defined as FFR>0.80.
Negative QFR is defined as QFR>0.80
|
1 hour
|
Diagnostic Performance of QFR in Comparison to FFR Reported as Positive and Negative Likelihood Ratio
Time Frame: 1 hour
|
Positive likelihood ratio is defined as sensitivity/(1-specificity).
Negative likelihood ratio is defined as (1-sensitivty)/specificity
|
1 hour
|
Diagnostic Grey Zone Calculation. QFR Limits for Achieving 95% Sensitivity and Specificity in Comparison to FFR
Time Frame: 1 hour
|
QFR limits to yield 95% sensitivity and specificity. The QFR limits are identified by Area under the receiver operating curve analysis. QFR limits are defined as the numerical QFR ratios (0-1.00). |
1 hour
|
Diagnostic Accuracy of TIMI-flow Based QFR in Comparison to 2D QCA (>50% Diameter Stenosis)
Time Frame: 1 hour
|
Comparison of proportion of participants correctly classified by QFR and 2D QCA using FFR as reference standard. Diagnostic accuracy is defined as (true positives + false negatives) / (true positives+false positives+true negatives+false negatives). Positive FFR is defined as FFR≤0.80. Positive QFR is defined as QFR≤0.80. Negative FFR is defines as FFR>0.80. Negative QFR is defines as QFR>0.80. Positive 2D QCA is defined as 2D-QCA % percent diameter stenosis >50. Negative 2D QCA is defined as 2D-QCA % diameter stenosis≤50. |
1 hour
|
Participants With Myocardial Infarction (Number of Patients)
Time Frame: 1 day
|
Peri-procedural myocardial infarction
|
1 day
|
All-cause Mortality (Number of Patients)
Time Frame: 1 day
|
Peri-procedural mortality
|
1 day
|
Time to FFR
Time Frame: 1 hour
|
Time from starting preparations to do FFR (e.g.
ordering assistants to prepare pressure wire, adenosine infusion etc.) to FFR value is obtained and drift has been verified to be within the prespecified limits
|
1 hour
|
Time to QFR After Receiving Angiographic Images
Time Frame: 1 hour
|
Time from first image evaluation on QFR computer until TIMI frame count based QFR value is obtained
|
1 hour
|
Contrast Use
Time Frame: 1 hour
|
Volume of contrast for total procedure
|
1 hour
|
Fluoroscopy Time
Time Frame: 1 hour
|
Fluoroscopy time for total procedure
|
1 hour
|
Collaborators and Investigators
Investigators
- Principal Investigator: Niels R. Holm, M.D., Aarhus University Hospital, Denmark
Publications and helpful links
General Publications
- Tu S, Westra J, Yang J, von Birgelen C, Ferrara A, Pellicano M, Nef H, Tebaldi M, Murasato Y, Lansky A, Barbato E, van der Heijden LC, Reiber JHC, Holm NR, Wijns W; FAVOR Pilot Trial Study Group. Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography: The International Multicenter FAVOR Pilot Study. JACC Cardiovasc Interv. 2016 Oct 10;9(19):2024-2035. doi: 10.1016/j.jcin.2016.07.013.
- Westra J, Andersen BK, Campo G, Matsuo H, Koltowski L, Eftekhari A, Liu T, Di Serafino L, Di Girolamo D, Escaned J, Nef H, Naber C, Barbierato M, Tu S, Neghabat O, Madsen M, Tebaldi M, Tanigaki T, Kochman J, Somi S, Esposito G, Mercone G, Mejia-Renteria H, Ronco F, Botker HE, Wijns W, Christiansen EH, Holm NR. Diagnostic Performance of In-Procedure Angiography-Derived Quantitative Flow Reserve Compared to Pressure-Derived Fractional Flow Reserve: The FAVOR II Europe-Japan Study. J Am Heart Assoc. 2018 Jul 6;7(14):e009603. doi: 10.1161/JAHA.118.009603.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1-10-72-219-16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
Clinical Trials on QFR (observational)
-
Niels Ramsing HolmCompleted
-
Seoul National University HospitalUlsan University Hospital; Severance Hospital; Keimyung University Dongsan Medical... and other collaboratorsCompleted
-
Contilia Clinical Research InstituteUnknownCoronary Artery Disease | Fractional Flow Reserve, MyocardialGermany
-
Samsung Medical CenterSeoul National University Hospital; Inje University; Chosun University Hospital; Dongsan Medical CenterCompletedIschemic Heart DiseaseKorea, Republic of
-
Seoul St. Mary's HospitalNational Research Foundation of Korea; Seoul Saint Mary's Hospital; Incheon Saint... and other collaboratorsCompleted
-
Azienda Ospedaliera Sant'Anna e San SebastianoUnknownCoronary Artery Disease | Percutaneous Coronary Intervention | STEMI - ST Elevation Myocardial InfarctionItaly
-
Ruijin HospitalMed-X Research Institute, Shanghai Jiao Tong UniversityRecruitingPrimary Valvular Heart Disease With Comorbid Coronary Artery Disease | Planned to Undergo Elective On-pump Valve Surgery Due to Primary Mitral and/or Aortic Valvular Heart DiseaseChina
-
Beijing Anzhen HospitalBeijing Municipal Science & Technology CommissionUnknownCoronary Artery Disease | Ischemic Heart DiseaseChina
-
Pulse Medical Imaging Technology (Shanghai) Co....Shanghai Chest HospitalUnknownMyocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Vascular Diseases | Coronary Artery Disease | Arteriosclerosis | Arterial Occlusive DiseasesChina
-
Hospital Clínico Universitario de ValladolidRecruitingCoronary OcclusionSpain